ICBs inhibit cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and PD-1 ligand 1 (PD-L1), which inhibit antitumor immune responses in the tumor microenvironment, and promote antitumor efficacy [2]. Here, CTLA4 is linked to neoplasm.